Samfara completa la adquisición de Chr. Olesen Synthesis, fabricante danés de APIs sujetos a control

Positive

AI Analysis

Summary

Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled APIs, backed by a consortium of European and North American institutional investors and family offices.

Importance:5/10

Sentiment:

0.50

acquisitionAPI manufacturingcontrolled substancesDenmarkinvestment

Read the original article

Published by PR Newswire Biotech on October 2, 2026 6:00 AM

Read Original